We are live on
!
Find out more
Iovance Biotherapeutics
IOVA
IOVA
131 hedge funds and large institutions have $1.02B invested in Iovance Biotherapeutics in 2018 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 48 increasing their positions, 30 reducing their positions, and 20 closing their positions.
New
Increased
Maintained
Reduced
Closed
238% more call options, than puts
Call options by funds: $5M | Put options by funds: $1.48M
60% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 30
25% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 20
4% more funds holding
Funds holding: 126 → 131 (+5)
1.8% more ownership
Funds ownership: 92.86% → 94.66% (+1.8%)
4% less capital invested
Capital invested by funds: $1.07B → $1.02B (-$47.5M)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
Holders
131
Holders Change
+5
Holders Change %
+3.97%
% of All Funds
2.99%
Holding in Top 10
7
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-12.5%
% of All Funds
0.16%
New
25
Increased
48
Reduced
30
Closed
20
Calls
$5M
Puts
$1.48M
Net Calls
+$3.52M
Net Calls Change
+$835K
Top Buyers
| 1 |
Citadel Advisors
Miami,
Florida
|
+$40.3M |
| 2 |
PA
Perceptive Advisors
New York
|
+$20.4M |
| 3 |
Fidelity International
Hamilton,
Bermuda
|
+$19M |
| 4 |
BC
Broadfin Capital
New York
|
+$10.6M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$7.52M |
Top Sellers
| 1 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$25.6M |
| 2 |
Millennium Management
New York
|
-$9.26M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.25M |
| 4 |
TCIM
TIAA CREF Investment Management
New York
|
-$5.09M |
| 5 |
GTC
Ghost Tree Capital
New York
|
-$4.61M |
